Accelerating Human Immune Disease Research:
Launch of the "Science Connect Program" Integrating Cutting-Edge Tech with Nippon BD

December 19, 2025

Center for Human Immunological Diseases and Therapy Development, Chiba university (cCHID), Chiba University, Synergy Institute for Mucosal Vaccine Research and Development (cSIMVa) and Nippon Becton Dickinson Company, Ltd. (Nippon BD) have signed a Memorandum of Understanding (MOU) as of December 4, 2025.

In line with this agreement, we have launched the “Science Connect Program” (SCP), an industry-academia collaboration initiative provided by Nippon BD. The program aims to integrate cutting-edge single-cell analysis technologies-ranging from cellular to genetic levels-to conduct detailed analyses of the diversity of the human immune system, elucidate pathological mechanisms, develop new therapies, and accelerate drug discovery.

The primary initiatives of this program:
1. Standardization of workflows for the comprehensive analysis of human immune diversity.
2. Establishment of core facilities for flow cytometry utilizing cutting-edge technologies.
3. Co-creation of new technological innovations built upon the foundation of international-standard technical infrastructure.

Through the promotion of this program, we will integrate the extensive expertise and clinical specimens in human immune pathology held by cCHID and cSIMVa with the state-of-the-art single-cell analysis technology provided by Nippon BD. This synergy will enable the acquisition of big data for the comprehensive analysis and global mapping of human immune system diversity. Furthermore, by collaborating with AI-driven data science, we aim to establish a world-class research infrastructure and a Shared Resource Laboratory (SRL), contributing to the elucidation of human immune diseases and the development of innovative therapies.